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ABSTRACT
Introduction: This 32-week, open-label, ran-
domized, parallel-group, multinational trial
aimed to compare the efficacy and safety of
stepwise insulin intensification of biphasic
insulin aspart 30 (BIAsp 30) relative to stepwise
intensification of a basal–bolus regimen in
insulin-naı¨ve adults with type 2 diabetes (T2D)
who continued pretrial treatment with met-
formin and sulfonylurea.
Methods: Adults with T2D were randomized
into one of two treatment arms for 32 weeks: (1)
BIAsp 30 once daily (OD), with the possibility of
stepwise treatment intensification up to
BIAsp 30 three times daily (TID); (2) insulin
glargine OD, with the possibility of stepwise
treatment intensification with insulin aspart up
to TID. The primary endpoint was change from
baseline in HbA1c after 32 weeks.
Results: After 32 weeks, the estimated mean
change in HbA1c from baseline was statistically
significantly lower in the BIAsp 30 arm
(- 1.18%) versus basal–bolus (- 1.36%) [esti-
mated treatment difference 0.18%; 95% confi-
dence interval (95% CI) 0.01; 0.36; p\0.05].
The proportion of patients with HbA1c below
7.0% was statistically significantly lower with
BIAsp 30 (42.9%) compared with basal–bolus
(56.9%) (odds ratio 0.58; 95% CI 0.37; 0.89;
p = 0.01). The overall rate of severe or blood
glucose (BG)-confirmed hypoglycemic events
was numerically lower for BIAsp 30 compared
with basal–bolus, and a statistically significantly
lower rate in nocturnal severe or BG-confirmed
hypoglycemia in the BIAsp 30 arm relative to
basal–bolus was observed: estimated rate ratio
0.32 (95% CI 0.13; 0.79), p = 0.0131. The pro-
portion of patients with adverse events was
similar in both treatment arms.
Conclusion: Insulin intensification with
BIAsp 30 and basal–bolus showed an improve-
ment in glycemic control; the change in HbA1c
was statistically significantly lower for BIAsp 30
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compared to basal–bolus. Basal–bolus treatment
was accompanied by a numerically, and statis-
tically significantly, higher rate of overall and
nocturnal severe or BG-confirmed hypo-
glycemia, respectively, compared with
BIAsp 30.
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INTRODUCTION
The progressive nature of type 2 diabetes (T2D)
necessitates initiation and intensification of
medication to achieve glycemic control and to
reduce the risk of diabetes-related complica-
tions [1]. For instance, the 10-year follow-up of
the UK Prospective Diabetes Study (UKPDS)
showed a sustained legacy effect of early,
intensive blood glucose control in significantly
decreasing the risk of myocardial infarction,
microvascular disease, and death from any
cause in patients with T2D [2]. Based on data
such as these, recent guidelines recommend
lowering HbA1c below 7.0% in most patients
and that insulin therapy should not be delayed
[3].
After metformin monotherapy, basal insu-
lins, such as the long-acting insulin analogues,
are often recommended as initial insulin ther-
apy [3, 4]. However, in many parts of the world,
a premix insulin containing both rapid-acting
and intermediate-acting components in one
formulation is also used to initiate or intensify
insulin treatment [5, 6]. Biphasic insulin aspart
30 (BIAsp 30) is one such analogue premix
insulin, which contains a mixture of soluble
insulin aspart (IAsp) 30% and protaminated
IAsp 70%, and is recommended to be injected
either once daily (OD), twice daily (BID), or
three times daily (TID) [7]. In insulin-naı¨ve
patients with T2D who have poor glycemic
control, initiation of BIAsp 30 has been shown
to significantly reduce HbA1c and has been
associated with a slight weight gain, but no
increased risk of severe hypoglycemic episodes,
compared with basal insulin only regimens
[8–12].
Following failure of adequately titrated basal
insulin and oral antidiabetic drugs (OADs) to
maintain glycemic control, the American Dia-
betes Association (ADA)’s recommended treat-
ment algorithm is stepwise intensification with
a rapid-acting prandial insulin added to a basal
insulin OD regimen (‘‘basal plus’’), up to three
injections of prandial insulin per day
(‘‘basal–bolus’’) [3, 13, 14]. The ADA also now
recommends that patients not achieving opti-
mal glycemic control on a basal only or a basal
plus regimen can switch to premix insulin BID,
which can be intensified to TID to achieve
optimal glycemic control [3, 15]. With regard to
basal plus versus premix BID regimens, clinical
evidence indicates that both regimens are
broadly comparable with regard to efficacy and
safety [16–19]. Equally, when further intensifi-
cation is needed, both basal–bolus and premix
TID regimens are now considered at the same
level of efficacy and safety [3, 8, 20]. Overall,
this parity emphasizes the important role of
patient-centered factors in clinical deci-
sion-making; for instance, factors such as regi-
men simplicity, experience of hypoglycemia,
and variability in patient lifestyles can all
dictate the success of an insulin intensification
regimen [3, 8, 19].
Whilst stepwise intensification of
basal–prandial and premix regimens are rec-
ommended treatment strategies [3], there is a
need to provide further clinical evidence for
their use in patients with T2D. Thus, based on
the lack of existing data, the aim of the current
trial in insulin-naı¨ve patients with T2D was to
compare the efficacy and safety of stepwise
insulin intensification with BIAsp 30 relative to
stepwise intensification with a basal–bolus reg-
imen of insulin glargine (IGlar) and IAsp.
METHODS
Design
This was a 32-week, open-label, randomized,
parallel-group, multicenter, multinational,
phase 4 trial in patients with T2D aged at least
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18 years (clinicaltrials.gov identifier,
NCT02453685). The trial was conducted in nine
countries: Australia, Bulgaria, Hungary, India,
Republic of Korea, Serbia, Thailand, Turkey, and
United Arab Emirates, between September 2015
and September 2016. The trial period consisted
of a screening period (up to 2 weeks before
randomization) and a 32-week treatment period
divided into four periods of 8 weeks each. All
procedures followed were in accordance with
the ethical standards of the responsible com-
mittee on human experimentation (institu-
tional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
Eligible participants were insulin-naı¨ve men
or women aged at least 18 years and had been
clinically diagnosed with T2D for at least
6 months prior to screening, were treated with a
stable daily dose (for at least 90 days prior to
screening) of metformin (at least 1000 mg or
maximum tolerated dose in the patient medical
record) and sulfonylurea (SU) and were willing
to discontinue any other OADs, including
insulin secretagogues (except SU), dipeptidyl
peptidase-4 inhibitor (DPP-4i), sodium glucose
co-transporter 2 inhibitor (SGLT2i), coleseve-
lam, bromocriptin, and/or combination prod-
ucts at randomization, had an HbA1c 7.0–9.5%
(both inclusive) and body mass index (BMI) less
than 40.0 kg/m2. Key exclusion criteria inclu-
ded previous participation in the current trial or
participation in another clinical trial 1 month
before screening, any contraindication to
BIAsp 30, IGlar, or IAsp, impaired liver function,
high blood pressure, proliferative retinopathy
or maculopathy requiring acute treatment,
mental incapacity, psychiatric disorder, unwill-
ingness or language barriers precluding ade-
quate understanding or co-operation.
Eligible patients were randomized (stratified
by pretrial OAD therapy) into one of two treat-
ment arms: (1) BIAsp 30 OD with the largest
meal, with the possibility of treatment intensi-
fication up to BIAsp 30 TID; (2) IGlar OD, with
the possibility of treatment intensification with
IAsp up to TID (basal–bolus).
Treatments, Insulin Dosing and Titration
Patients were instructed in trial product
administration and the investigator docu-
mented that direction for use was given to the
patient orally and in writing at the first dis-
pensing visit. Subsequent directions for use
were given at succeeding visits if deemed
appropriate by the investigator. It was the
investigator’s or delegated staff’s responsibility
to assess if the patient was capable of following
instructions during training and those in the
directions for use.
Pretrial treatment with metformin and SU
was continued as background treatment
throughout the entire trial, in line with the
treatment practice demonstrated in the
A1chieve study [21]. The stable dose levels and
dosing frequencies prescribed pretrial could be
changed for safety reasons only, at the discre-
tion of the investigator. An individualized
approach to insulin titration and intensification
regimen was used in the current trial as opposed
to using fixed insulin doses. All patients
underwent a weekly insulin dose titration dur-
ing the entire treatment period in order to
achieve the pre-meal self-monitored plasma
glucose (SMPG) target of 4.4–6.1 mmol/L
(80–110 mg/dL).
At the end of each 8-week period (weeks 8,
16, and 24), insulin treatment was intensified in
a stepwise manner by adding an additional
injection of BIAsp 30 in the BIAsp 30 arm, and
IAsp in the basal–bolus arm, on the basis of
whether patients had achieved target HbA1c
below 7.0%. The insulin treatment could only
be stepwise intensified at the appropriate
8-week period. Patients randomized to BIAsp 30
had the possibility of receiving up to three daily
injections of BIAsp 30 and patients randomized
to basal–bolus had one daily injection of IGlar
plus the possibility of up to three daily injec-
tions of IAsp. In the BIAsp 30 arm, patients
received BIAsp 30 OD at a starting dose of 12 U
administered with the largest meal. In the event
of intensification to twice- or thrice-daily
injections of BIAsp 30, the second or third
injection was given at the second or third
Diabetes Ther (2018) 9:1–11 3
largest meal, respectively. Patients randomized
to the basal–bolus arm received IGlar OD at a
starting dose of 10 U administrated at the same
point of time every day. For patients receiving
IGlar OD who were intensified to once-, twice-,
or thrice-daily insulin injections with IAsp, the
first, second, or third injection was given at the
first, second, or third largest meal, respectively,
with a starting dose of 4 U.
Efficacy and Safety Endpoints
The primary endpoint was change from baseline
in HbA1c after 32 weeks of treatment. Secondary
endpoints included the proportion of patients
achieving HbA1c below 7% after 32 weeks of
treatment (total and without severe hypo-
glycemia during the last 12 weeks of treatment),
change from baseline in fasting plasma glucose
(FPG) after 32 weeks of treatment, mean 7-point
SMPG profiles and prandial plasma glucose (PG)
increments after 32 weeks of treatment, total
daily insulin dose during the 32 weeks of treat-
ment, and change in patient-reported diabetes
treatment satisfaction from baseline to 32 weeks
of treatment assessed by the diabetes treatment
satisfaction questionnaire (DTSQ) [22]. Safety
endpoints included the number of treat-
ment-emergent hypoglycemic episodes classi-
fied according to the Novo Nordisk definition of
confirmed symptomatic hypoglycemia during
32 weeks of treatment, change in body weight
from baseline to 32 weeks of treatment, inci-
dence of adverse events (AEs) during 32 weeks
of treatment, and change in clinical safety
parameters (physical examination, vital signs,
laboratory parameters) from baseline to
32 weeks of treatment.
Statistics
Sample size was based on the half-width of a 95%
confidence interval (CI) for the difference
between the two means of change from baseline
in HbA1c for the full analysis set (FAS) (i.e., all
randomized patients). The sample size was deter-
mined byrequiring thathalf the lengthof the95%
confidence interval was less than 0.27 with 90%
probability. To ensure this, 336 patients needed to
be randomized. Thus, assuming a screening fail-
ure rate of 30%, 480 patients were needed to be
screened for inclusion in the trial.
Change from baseline in HbA1c after
32 weeks of randomized treatment was ana-
lyzed using a mixed model repeated measure-
ment (MMRM) where all calculated changes in
HbA1c from baseline at weeks 4, 7, 12, 15, 20,
23, 28, and 32 were included in the analysis.
This model included treatment, region, and
strata (two levels: pretrial metformin and SU,
with/without other OAD) as fixed effects,
HbA1c at baseline as covariate, and interactions
between all fixed effects and visit, and between
the covariate and visit. A dichotomous (re-
sponder/non-responder) endpoint was defined
on the basis of whether a patient had met
HbA1c below 7.0% after 32 weeks of random-
ized treatment (overall and without severe
hypoglycemia during the last 12 weeks of
treatment). As a conservative approach,
patients withdrawn before 32 weeks were
defined as non-responders. It was analyzed
using a logistic regression model with treat-
ment, strata, and region as factors, and base-
line HbA1c as covariate. Changes from baseline
in FPG after 32 weeks of randomized treatment
were analyzed on the basis of all planned
post-baseline measurements until or at
32 weeks using an MMRM similar to the model
used for analysis of the primary endpoint,
except with the respective baseline value as
covariate. Prandial PG increment for each meal
(breakfast, lunch, main evening meal) was
derived from the 7-point SMPG profile as the
difference between prandial 90-min PG values
and the PG value before meal in each separate
profile. Mean 90-min postprandial glucose
increments over all meals were derived as the
mean of all corresponding meal increments.
Prandial PG increment endpoints (mean and
each separate meal) were analyzed on the basis
of all planned post-baseline measurements
until or at 32 weeks using an MMRM similar to
the model used for analysis of the primary
endpoint and with the corresponding baseline
value as covariate.
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RESULTS
Of the 481 patients screened, 146 were screen-
ing failures. A total of n = 335 patients were
randomized and all randomized patients were
exposed, except for three patients [all three
unexposed patients were included in the FAS,
but none of them were included in the safety
analysis set (i.e., all patients receiving at least
one dose of the investigational product or its
comparator)]. Overall, n = 166 patients were
exposed to the BIAsp 30 arm and n = 166
patients were exposed to the basal–bolus arm.
Baseline characteristics were comparable across
treatment arms (Table 1).
After 32 weeks of treatment, the observed
mean HbA1c was reduced to 7.1% in the
BIAsp 30 arm and 6.9% in the basal–bolus arm
(Fig. 1). The estimated mean change in HbA1c
from baseline to week 32 was statistically sig-
nificantly lower in the BIAsp 30 arm (- 1.18%)
compared with the basal–bolus arm (- 1.36%)
[estimated treatment difference (ETD) 0.18%;
95% confidence interval (95% CI) 0.01; 0.36;
p\0.05]. In Fig. 2, the observed mean HbA1c
over time can be seen for patients on the basis
of the regimen and treatment that they were on
after 24 weeks of treatment. The resulting HbA1c
levels are a consequence of the trial design, as
treatments were intensified on the basis of the
patients’ glycemic target throughout the trial.
Hence, patients that were in good control on
average at intensification visits did not intensify
their treatment, whereas the opposite was the
case for patients with HbA1c above 7%. As a
result of this trial design, as the initial
Fig. 1 Mean HbA1c over time. BIAsp 30, biphasic insulin
aspart 30
Fig. 2 Observed mean HbA1c over time by treatment
regimen. Full analysis set, observed data. BIAsp 30 biphasic
insulin aspart 30, BID twice daily, IAsp insulin aspart, IGlar
insulin glargine, OD once daily, TID three times a day
Table 1 Baseline characteristics
Characteristic BIAsp 30 Basal–bolus
Full analysis set, N 168 167
Sex, N (%)
Male 89 (53.0) 77 (46.1)
Female 79 (47.0) 90 (53.9)
Age (years) 56.6 (10.4) 56.5 (10.1)
Body weight (kg) 78.2 (16.5) 80.6 (14.8)
BMI (kg/m2) 28.6 (4.6) 29.8 (4.6)
Height (m) 1.6 (0.1) 1.6 (0.1)
HbA1c (%) 8.3 (0.7) 8.2 (0.7)
FPG (mmol/L) 9.7 (2.7) 9.6 (2.3)
Data are mean (SD)
BIAsp 30 biphasic insulin aspart 30, BMI body mass index,
FPG fasting plasma glucose
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randomization was not preserved, no conclu-
sions on treatment comparisons can be made.
The proportion of patients who achieved HbA1c
below 7.0% after 32 weeks of treatment was statis-
tically significantly lower in the BIAsp 30 arm
(42.9%) compared with the basal–bolus arm
(56.9%) [odds ratio (OR) 0.58; (95% CI) 0.37; 0.89;
p= 0.01].Theproportionof patientswhoachieved
HbA1c below 7.0% after 32 weeks of treatment
without severe hypoglycemia during the last
12 weeksof treatmentwasstatistically significantly
lower in the BIAsp 30 arm (42.3%) compared with
the basal–bolus arm (56.3%) [OR 0.58; (95% CI
0.37; 0.89); p= 0.01].
The estimated mean reduction in FPG was
statistically significantly lower at week 32 in the
BIAsp 30 arm (- 1.93 mmol/L) compared with
the basal–bolus arm (- 2.72 mmol/L) [ETD 0.79
(95% CI 0.23; 1.35); p\0.01].
The estimated mean of the mean prandial PG
increment was statistically significantly lower at
week 32 in the BIAsp 30 arm (1.29 mmol/L)
compared with the basal–bolus arm
(1.85 mmol/L) [ETD - 0.55 mmol/L (95% CI
- 0.97; - 0.14); p\0.01]. The estimated mean
prandial PG increments were statistically sig-
nificantly lower at breakfast [- 0.61 mmol/L
(95% CI - 1.20; - 0.02); p\0.05] and dinner
[– 0.77 mmol/L (95% CI - 1.43; - 0.12);
p\0.05] for BIAsp 30 compared with basal–bo-
lus, whereas the difference at lunch
[- 0.13 mmol/L (95% CI - 0.70; 0.44); p = 0.66]
was not statistically significant.
The mean total daily insulin dose increased
throughout the treatment period with no pro-
nounced differences between BIAsp 30 and
basal–bolus; from 0.157 U/kg at baseline to
0.700 U/kg at week 32 for BIAsp 30 and from
0.127 U/kg at baseline to 0.708 U/kg at week 32
for basal–bolus.
At week 8, the proportion of patients who
intensified treatment was 73.5% in the BIAsp 30
arm and 71.7% in the basal–bolus arm. At week
16, 46.4% and 48.2% of patients had their
treatment intensified in the BIAsp 30 arm and
basal–bolus arms, respectively. At week 24, the
proportion was 13.9% and 35.5% in the
BIAsp 30 and basal–bolus arms, respectively.
The low proportion of patients in the BIAsp 30
arm who had their insulin treatment intensified
at week 24 can potentially be explained by there
being no further options for insulin intensifi-
cation for patients who already had been
intensified to the maximum number of three
injections at week 16.
At week 24, 87 out of 149 patients in the
BIAsp 30 arm were prescribed the maximum
number of injections (three injections) and 42
out of 156 patients in the basal–bolus arm were
prescribed the maximum number of injections
(four injections). There were 18 out of 149
patients receiving BIAsp 30 OD and 31 out of
156 patients receiving IGlar OD, with 42 out of
156 patients receiving IGlar OD plus IAsp OD.
Forty-four out of 149 patients were receiving
BIAsp 30 BID and 41 out of 156 patients were
receiving IGlar OD plus IAsp BID.
The overall rate of severe or BG-confirmed
hypoglycemia (Novo Nordisk classification) was
4.24 episodes/patient-year of exposure (PYE) in
the BIAsp 30 group and 5.2 episodes/PYE in the
basal–bolus group: estimated rate ratio 0.83
(95% CI 0.58; 1.19); p = 0.3061 (Table 2). There
were four severe hypoglycemia episodes in the
BIAsp 30 arm and 20 episodes reported in the
basal–bolus arm (Table 2). A mean cumulative
plot of severe or BG-confirmed hypoglycemia is
reported in Fig. 3. The observed rate of severe or
BG-confirmed nocturnal hypoglycemia [defined
as an episode that occurred between 00:01 and
05.59 (both inclusive)] was 0.53 episodes/PYE
for BIAsp 30 and 0.98 episodes per PYE for
basal–bolus. A post hoc analysis showed that
the rate of severe or BG-confirmed nocturnal
hypoglycemia was statistically significantly dif-
ferent: mean rate ratio 0.32 (95% CI 0.13; 0.79),
p = 0.0131.
After 32 weeks of treatment, an increase in
observed mean body weight was seen in both
treatment arms: ? 2.49 kg in the BIAsp 30 arm
and ? 2.36 kg in the basal–bolus arm.
Overall, the proportion of patients with AEs
was similar in both the BIAsp 30 (48.8%) and
basal–bolus (46.4%) arms (Table 3). The number
of severe AEs was lower in the BIAsp 30 arm
than the basal–bolus arm (Table 3). Of the nine
severe AEs observed in the BIAsp 30 arm, none
were related to hypoglycemia whereas eight of
the 15 severe AEs observed in the basal–bolus
arm were related to hypoglycemia. There were
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three episodes of hypoglycemic unconscious-
ness in the basal–bolus arm and none in the
BIAsp 30 arm. One patient in the basal–bolus
arm died during the trial from cerebellar
infarction, which was considered unlikely rela-
ted to the trial product.
Quality of life was assessed by the DTSQ that
was completed by patients at randomization
and after 32 weeks of treatment. The DTSQ
contained eight questions, of which six related
to the overall treatment satisfaction and two to
glycemic control. For the overall treatment sat-
isfaction, a higher score (0–36) was related to a
better perception of treatment satisfaction. For
hypoglycemia and hyperglycemia, a lower score
(0–6) was related to a better blood glucose
control. The median (min; max) DTSQ score for
overall treatment satisfaction at week 32 was 33
(6; 36) in the BIAsp 30 arm and 32 (6; 36) in the
basal–bolus arm and the median change from
baseline was 3 (- 24; 26) and 4 (- 27; 30) in the
BIAsp 30 and basal–bolus arms, respectively.
The median (min; max) DTSQ score for hyper-
glycemia at week 32 was 2.0 (0; 6) in the
BIAsp 30 arm and 1.0 (0; 6) in the basal–bolus
arm and the median change from baseline was
- 1 (- 6; 5) and - 2 (- 6; 4) in the BIAsp 30 and
basal–bolus arms, respectively. The median
(min; max) DTSQ score for hypoglycemia at
week 32 was 2.0 (0; 6) in the BIAsp 30 arm and
2.0 (0; 6) in the basal–bolus arm and the median
change from baseline was 1 (- 6; 6) and 1 (- 6;
6) in the BIAsp 30 and basal–bolus arms,
respectively.
DISCUSSION
In this population of insulin-naı¨ve patients with
T2D who continued pretrial treatment with
metformin and SU, insulin intensification with
both BIAsp 30 and basal–bolus showed an
improvement in glycemic control as measured
by reductions in HbA1c. Compared with
BIAsp 30, basal–bolus treatment resulted in a
greater reduction in HbA1c from baseline, a
higher proportion of patients achieving HbA1c
Fig. 3 Severe or BG-conﬁrmed treatment-emergent hypo-
glycemia cumulative plot. BIAsp 30, biphasic insulin aspart 30
Table 2 Summary of treatment-emergent hypoglycemia
BIAsp 30 Basal–bolus
N % E R N % E R
Severe 3 1.8 4 0.04 11 6.6 20 0.21
Severe or BG-conﬁrmed 93 56.0 400 4.24 90 54.2 505 5.16
Safety analysis set. Treatment emergent: if the onset of a hypoglycemic episode occurs on or after the ﬁrst day of trial
product administration, and no later than the last day of randomized treatment. Severe hypoglycemia: an episode requiring
assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. PG concen-
trations may not be available during an event, but neurological recovery following the return of PG to normal is considered
sufﬁcient evidence that the event was induced by a low PG concentration. Severe or BG-conﬁrmed: an episode that is severe
according to the ADA classiﬁcation or blood glucose conﬁrmed by a PG value\3.1 mmol/L (56 mg/dL) with symptoms
consistent with hypoglycemia
% percentage of patients, BG blood glucose, BIAsp 30 biphasic insulin aspart 30, E events, N number of patients, R event
rate per patient-year of exposure
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below 7% (overall and without severe hypo-
glycemia during the last 12 weeks of treatment),
along with a greater reduction in FPG. However,
the estimated mean prandial PG increments
were statistically significantly lower at breakfast
and dinner for the BIAsp 30 arm compared with
the basal–bolus arm, whereas the difference at
lunch was not statistically significant. The
overall rate of severe or BG-confirmed hypo-
glycemic events was numerically lower for
BIAsp 30 compared with basal–bolus, with a
post hoc analysis indicating that the overall rate
of severe or BG-confirmed nocturnal hypo-
glycemia was statistically significantly lower
with BIAsp 30 compared with basal–bolus.
Overall, BIAsp 30 and basal–bolus treatments
were safe and well-tolerated and no unexpected
safety issues were identified, with the propor-
tion of patients with AEs and the number of AEs
being similar for both treatments.
On the basis of clinical evidence, the ADA
now state that premix BID has parity with basal
plus as an intensification strategy following
failure of basal insulin (usually with met-
formin ± other non-insulin agent) to achieve
glycemic control [3, 16–19]. Furthermore, pre-
mix TID and basal–bolus regimens are now
viewed as having comparable efficacy and
safety, where patients may switch between the
two to achieve optimal glycemic control
[3, 8, 20]. When appraising the results of the
current trial within the patient-centered model
of treatment of T2D, the importance of achiev-
ing optimal control of HbA1c may be overridden
by the importance of preventing hypoglycemia
for certain patients, with hypoglycemia having
a number of deleterious physical and
psychological outcomes that can significantly
impair patient functioning [23, 24].
When intensifying treatment with a patient
who has failed to achieve glycemic control with
basal insulin OD and OADs, a full basal–bolus
regimen provides a more flexible possibility to
fine-tune dosing in relation to meals etc.
Table 3 Summary of treatment-emergent AEs
AEs BIAsp 30 (N5 166) Basal–bolus (N5 166)
N % E R N % E R
All 81 48.8 277 2.93 77 46.4 319 3.26
Serious 14 8.4 21 0.22 12 7.2 22 0.23
Severe 6 3.6 9 0.09 8 4.8 15 0.15
Moderate 29 17.5 40 0.42 37 22.3 95 0.97
Mild 68 41.0 228 2.42 64 38.6 209 2.14
Possibly related to trial product 3 1.8 4 0.04 6 3.6 6 0.06
Probably related to trial product 5 3.0 5 0.05 12 7.2 42 0.43
Preferred term[5%
Nasopharyngitis 21 12.7 31 0.33 18 10.8 27 0.28
Upper respiratory tract infection 11 6.6 15 0.16 11 6.6 13 0.13
Back pain 11 6.6 13 0.14 8 4.8 9 0.09
Arthralgia 11 6.6 16 0.17 6 3.6 7 0.07
Headache 12 7.2 24 0.25 15 9.0 27 0.28
Diarrhea 10 6.0 19 0.20 11 6.6 12 0.12
% percentage of patients, AE adverse event, BIAsp 30 biphasic insulin aspart 30, E number of episodes, N number of
patients, R rate per patient-year of exposure
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However, many clinicians find that premix
insulin has advantages over a basal–bolus insu-
lin regimen. For instance, current guidance
suggests that premix insulin regimens may have
greater simplicity, require fewer injections and
self-measured blood glucose monitoring, and be
more practical for patients with physical dis-
abilities [25]. A premix regimen may be more
suitable for patients with regular meals and a
large, consistent carbohydrate intake [19]. Pre-
mix insulin regimens require only one injection
device and this has the potential to reduce the
risk of mix-ups that can often be observed when
patients have to manage multiple devices dur-
ing basal–bolus therapy.
There are limitations of the current trial that
should be discussed. For example, on the basis
of our clinical experience, it is likely that
achieving HbA1c below 7% in 8 weeks with a
premix regimen alongside metformin and SU,
in the absence of hypoglycemia, would be a
challenge for many patients with T2D. Further,
although the A1chieve study in real-world clin-
ical practice showed a significant reduction in
HbA1c with a relatively low rate of hypo-
glycemia when patients began or changed to
insulin analogue therapy and continued met-
formin and SU, the design of the current trial
differed. Specifically, in A1chieve, the partici-
pant and physician determined the choice and
starting dose of insulin, administration fre-
quency, and any later changes to either dose or
frequency [21]. An additional limitation could
also be argued to be the open-label nature of the
trial, which was required as blinding of the
insulin interventions was considered inappro-
priate and would have resulted in a requirement
for placebo injections. Lastly, because of the
way that hypoglycemia was assessed in the
current trial, episodes of nocturnal hypo-
glycemia may not have been recorded if the
patient was asleep (i.e., nocturnal hypoglycemia
unawareness).
CONCLUSIONS
Insulin intensification with BIAsp 30 and
basal–bolus showed an improvement in gly-
cemic control; the change in HbA1c was
statistically significantly lower for BIAsp 30
compared to basal–bolus. A numerically greater
rate of overall severe or BG-confirmed hypo-
glycemia and a statistically significantly higher
rate of severe or BG-confirmed nocturnal
hypoglycemia was observed with basal–bolus
compared with BIAsp 30. Viewed within the
context of the patient-centered model of
treatment, these results may translate to clini-
cally relevant considerations for patients with
T2D.
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